Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

Background

Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (

Objective

We evaluated the impact of SNPs of

Patients and methods

We included 314/491 patients from PRODIGE 9 with a DNA blood sample available. Nine SNPs were genotyped on germline DNA using real-time Polymerase Chain Reaction TaqMan TM (Thermo Fisher Scientific, Waltham, MA , USA 02451).

Results

In the bevacizumab arm, patients with the

Conclusion

Among mCRC patients treated with bevacizumab maintenance, those with the

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships that may be considered as potential competing interests: JT received honoraria as a speaker or in an advisory role from Amgen, Astellas, BMS, Merck-Serono, MSD, Novartis, Pierre Fabre, Roche, and Servier; O.B. received personal fees as a speaker and/or an advisor from Merck KGaA, Roche, Bayer, Astra-Zeneca, Grunenthal, MSD, Amgen, Sanofi, Servier, and Pierre Fabre, outside the submitted work; VB received personal fees, and non-financial support from Merck Serono, Bayer, Roche, Sanofi, Ipsen, Merck MSD, BMS, Eisai, Novartis, and Amgen outside the submitted work. BDR, CSB, AF, KLM, JB, FG, TC, RF, EF, SJ, DG, CM, SO, JFS, TA, and LD declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. JT has received honoraria as a speaker or an advisor from Amgen, Astellas, BMS, Merck-Serono, MSD, Novartis, Pierre Fabre, Roche, and Servier. VB received personal fees and non-financial support from Merck Serono, Bayer, Roche, Ipsen, Merck MSD, Amgen, non-financial support from Sanofi, personal fees from BMS, Eisai, Novartis, outside the submitted work. O.B. received personal fees as a speaker and/or advisor from Merck KGaA, Roche, Bayer, Astra-Zeneca, Grunenthal, MSD, Amgen, Sanofi, Servier, and Pierre Fabre, outside the submitted work.